# Indiana Hemophilia and Thrombosis Center

Indiana Hemophilia and Thrombosis Center is an Endowment / Foundation based in Indianapolis, United States.

## Overview

- **Organization type:** Endowment / Foundation
- **Headquarters:** Indianapolis, United States
- **Region:** North America
- **Address:** 8326 Naab Road, Indianapolis, IN 46260, United States
- **Founded:** 1998
- **Assets under management:** Undisclosed
- **Website:** innovativehematology.org
- **LinkedIn:** https://www.linkedin.com/company/innovative-hematology-inc

## Regulatory record

- **Reports private funds:** No

## About

Shapiro and Greist founded the Indiana Hemophilia and Thrombosis Center (IHTC) in 1998 under the parent entity Innovative Hematology, Inc. The center operates as Indiana's sole federally designated hemophilia treatment center, a structural monopoly that routes rare-disease patients, clinical research contracts, and pharmaceutical partnerships through a single care network. IHTC treats hemophilia, thrombosis, von Willebrand disease, HHT, and sickle cell disease, serving as a Center of Excellence recognized for patient care, education, and clinical research. IHTC's economic model fuses fee-for-service clinical revenue with pharmaceutical-sponsored trial income. The center runs a dedicated Gene Therapy Hub in Indianapolis, hosting industry trials for novel hemophilia gene therapies. Its institutional partner network includes the Indiana University School of Medicine, which provides long-standing clinical training support and financial backing. The Hemophilia Alliance and the American Thrombosis and Hemostasis Network (ATHN) integrate IHTC into national drug-purchasing coalitions and outcomes-research infrastructure that amplify its negotiating position with drug manufacturers. Eddie Williams, a senior global life sciences executive, serves on the board of Innovative Hematology, Inc. Effective April 2026, Sanjay P. Ahuja assumed the combined role of CEO and Medical Director, marking a formal succession from the founding clinical leadership team. IHTC is not structured as a traditional grantmaking foundation or pooled endowment. It operates as a clinical operating company with an asset-owner balance sheet — a hybrid that generates recurring revenue from patient encounters and pharmaceutical contracts while building long-term capital. That architecture makes it a rare entity in institutional portfolios: a healthcare provider whose investment reserves sit inside an operating nonprofit, governed by a board with pharmaceutical and life-sciences expertise rather than endowment-consultant orthodoxy.

## Sectors

- Healthcare Services
- Digital Health

## Offices

- Indianapolis, IN (Gene Therapy Hub)

## People

- Sanjay P. Ahuja — Chief Executive Officer & Medical Director
- Amy Shapiro — Co-Founder, Co-Medical Director
- Anne Greist — Co-Founder, Co-Medical Director
- Eddie Williams — Board Member, Innovative Hematology, Inc.

## Questions

### How is the Indiana Hemophilia and Thrombosis Center structured as an asset owner?

IHTC sits inside the nonprofit parent Innovative Hematology, Inc., not as a standalone grantmaking foundation. Its balance sheet builds from clinical operating revenue — patient visits, pharmaceutical-sponsored trial contracts — rather than a single family's liquidity event. This structure creates an endowment-like pool of capital governed by a board with deep pharmaceutical and life-sciences expertise.

### What role does IHTC play in the hemophilia gene-therapy market?

IHTC operates a dedicated Gene Therapy Hub in Indianapolis that runs clinical trials for novel hemophilia gene therapies. As one of the largest federally recognized hemophilia treatment centers in the U.S., it provides pharmaceutical companies with access to a concentrated rare-disease patient population, making it an active economic participant in the drug-development value chain.

### Who controls capital allocation decisions at IHTC?

Governance flows through the board of Innovative Hematology, Inc., which includes senior global life sciences executive Eddie Williams. As of April 2026, Sanjay P. Ahuja serves as CEO & Medical Director, succeeding co-founders Amy Shapiro and Anne Greist in the top management role. This dual clinical-executive office holds substantial influence over the balance-sheet strategy.

### Does IHTC invest directly in pharmaceutical or healthcare companies?

IHTC is not a known direct investor in portfolio companies. Its economic ties to the pharmaceutical sector come through clinical research contracts and trial-site revenue, not equity stakes. The institution's reserves grow from operating surpluses generated by those contracts, but any external investment portfolio remains undisclosed.

## Related profiles

- [Indiana Farm Bureau Retirement Plan](https://altss.com/profile/indiana-farm-bureau-retirement-plan)
- [Indiana/Kentucky/Ohio Regional Council of Carpenters Pension Fund](https://altss.com/profile/indiana-kentucky-ohio-regional-council-of-carpenters-pension-fund)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/indiana-hemophilia-and-thrombosis-center

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology